CellMed is developing encapsulated cellular systems for the delivery of therapeutic substances right in the patient. CellMed uses proprietary encapsulation technology and a cell line based on mesenchymal stromal cells. The cells are designed to secrete the desired proteins or peptides. These systems are produced according to GMP and are currently in clinical trials for the treatment of stroke. The engineered peptide here is a proprietary version of GLP-1 with specific anti-apoptotic properties.
